HDACs inhibitors are generally capable of causing the upregulation of MDR1, then inducing a broad and pleiotropic drug resistance of AML cells by regulating multiple ABC transporter genes, which is associated to poor prognosis.69 The gene discussed is ABCB1; the disease is acute myeloid leukemia.